Biotech | September 08, 2021
Biocon settles suit with Celgene for generic Revlimid
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Labetalol hydrochloride injection USP is indicated for the control of blood pressure in severe hypertension.
First launched in 2005, pharmaREADY is a fully integrated, regulatory compliant, web-based platform to create, view, and manage global regulatory submissions
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market
Subscribe To Our Newsletter & Stay Updated
